Bullous pemphigoid (BP) is the most common autoimmune subepidermal blistering disease of the skin. Investigation of the BP-associated pathophysiological processes during the last decades showed that the generation of autoantibodies directed against the hemidesmosome proteins BP180 and BP230, a hallmark of the BP-associated autoimmune response, leads to the recruitment of inflammatory immune cells at the dermal-epidermal junction, and subsequently to the release of a large amount of inflammatory molecules involved in blister formation. Analysis in transversal and longitudinal studies of autoantibodies and inflammatory molecules production both at the time of diagnosis and under treatment was mainly performed within the serum but also in the blister fluid. Some autoimmune or inflammatory molecules expression was related to the presence of clinical signs, while others were mere bystanders. In this review, we focused on the autoimmune and inflammatory molecules that have been identified as potential biomarkers of BP development and outcome.
| INTRODUCTION
Bullous pemphigoid (BP) is the most common autoimmune subepidermal blistering disease of the skin in Western countries, [1] affecting the elderly typically. However, despite all the clinical and pathophysiological investigations performed over the last decades, the complex mechanisms on which this disease develops and progresses are not fully understood yet. Activation of signalling pathways leading to autoantibody-induced pathology greatly differs among different diseases. [2] In BP, the autoimmune response of the disease is characterized by the presence of autoantibodies directed against the hemidesmosome proteins BP180 and BP230. The inflammatory response is characterized by the accumulation at the dermal-epidermal junction of numerous inflammatory immune cells, such as mast cells, eosinophils, neutrophils and basophils. [3] Notably, in patients with BP, eosinophils are found abundantly at the lesion site [4] and the increase in their number in peripheral blood has also been recognized as a characteristic of the disease. [5] These inflammatory cells release a potent army of cytokines, histamine, chemokines, proteinases, highly basic proteins and reactive oxygen species causing damages to tissues and amplifying the recruitment of other inflammatory cells. [6] [7] [8] [9] [10] Many markers of autoimmunity and inflammation are elevated in blister fluid and/or sera of BP patients, most of them are related to disease activity at the time of diagnosis.
To challenge both inflammation and autoimmunity components of BP, superpotent topical corticosteroids have proven their efficacy and subsequently are currently used as the first line of treatment in France. [11] Nevertheless, clinical relapse under therapy is still observed within the first year of treatment in approximately 30% of patients with BP. Clinical features and bullous pemphigoid disease area Giusti , Le Jan, Bernard, Pham, Antonicelli equally contributed to this study.
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index (BPDAI) already allow measuring disease severity and activity upon treatment. [12] Although such a valuable tool has still not been largely exploited, several parameters of this score such as the number of blisters a day and the body surface affected have been used to evaluate the relevance of different biomarkers associated with BP treatment efficacy and with BP outcome. The aim of this review was to compile published data from 1980 to 2017 to highlight soluble biomarkers involved in the activation of the autoimmune and inflammatory responses with respect to BP disease activity and outcome. BP180 antigen is the major target of autoantibodies from patients with BP. As a transmembrane protein, the extracellular part of BP180 makes it a privileged antigenic target in BP, especially the NC16A domain against which autoantibodies are produced and found in serum of most patients with BP. [18] Additional antigenic sites exist all along BP180 sequence, which have been associated with the non-inflammatory component of BP. [19] Using commercially available ELISAs, anti-BP180 NC16A autoantibodies are detected in 72%-93% of BP cases, [20] [21] [22] [23] [24] and serum levels at diagnosis have been correlated with disease activity. [23] [24] [25] Due to the high frequencies of detection of BP180 NC16A IgG in BP patients, these antibodies are part of the laboratory criteria for BP diagnostic. [26] Furthermore, the pathogenic role of BP180 NC16A IgG autoantibodies was evidenced by both in vitro and in vivo studies. [27] [28] [29] [30] [31] [32] Most data were generated in neonatal mice in which the injection of rabbit antimurine BP180 antibodies duplicated major characteristics of the human disease. [29, 33] In BP patients, several studies demonstrated a relationship between the titre of BP180 NC16A IgG and the disease severity [22, 34, 35] and a fluctuation of these titres between days 0, 60 and 150 may predict outcome. [36] In this line, treatment with adjuvant immunoadsorption or rituximab combined or not with intravenous immunoglobulins that reduce BP180 autoantibody concentration has been associated with clinical improvement and allows progressive withdrawal of corticosteroid or other immunosuppressants. [37] [38] [39] [40] [41] [42] Circulating antibasement membrane autoantibodies are mainly of the IgG isotype, with the IgG4 and IgG1 as the predominant IgG subclasses represented. [43] However, autoantibodies of the IgE type recognizing the NC16A domain of BP180 were also described with variable frequency in BP patients at diagnosis, probably explained by the different technics and serum dilutions used. [44] As for the IgG isotype, serum levels of anti-BP180 NC16A IgE were correlated with disease activity [43, [45] [46] [47] and disappearance of these antibodies was associated with clinical remission. [48, 49] The pathogenicity of specific anti-BP180 IgE has been proven by several in vitro experiments [50] [51] [52] and by in vivo mouse models. [53, 54] Similarly, the therapeutic benefits brought by the selective suppression of the IgE activity by omalizumab, in BP patients resistant to corticotherapy, are also an argument for the IgE pathogenicity. [55] [56] [57] [58] Actually, autoantibodies against BP180 are not specific to BP, as serum autoantibodies against the NC16A domain of BP180 are also detected by ELISA in almost 33% of patients with mucous membrane pemphigoid. [59] The differential diagnosis between BP and mucous membrane pemphigoid [60] is sometimes difficult, and classification relies on both clinical signs, that is, the presence of obvious scarring tendency of involved mucosal sites and limited skin involvement, and on immunological characterization of circulating autoantibodies. [61] [62] [63] [64] [65] [66] In this line, a multivariant ELISA for the simultaneous detection of IgG autoantibodies against major autoimmune bullous disease target antigens was established to help for the serologic diagnosis of almost all pemphigus and most pemphigoid disorders. [67, 68] In contrast to BP180-specific antibodies, the pathogenicity of anti-BP230 IgG remains undetermined. These autoantibodies detected by ELISA in 57%-63% of BP cases [23, 24, [69] [70] [71] [72] may be useful at diagnosis with a diagnostic added value of 5% compared with BP180 alone. [23] However, BP230 ELISA score at diagnosis does not correlate with disease activity, [23] but seems to be associated with localized types of BP. [73] Due to the intracellular location of BP230 protein and to the very low frequency of detection of these antibodies alone, it has been postulated that their presence was the consequence of an epitope spreading phenomenon. [74, 75] Furthermore, in vivo and ex vivo experimental models of specific anti-BP230 IgG passive transfer failed to fully reproduce characteristics of BP, that is, granulocyte recruitment, complement activation and subepidermal splitting. [76] [77] [78] As anti-BP180 antibodies, antibodies of IgE type recognizing BP230 were also detected in blister fluids and sera of BP patients, and their presence was associated with eosinophil accumulation. [79] With regard to BP disease outcome, recent studies demonstrated that the fluctuations of anti-BP180 IgG autoantibody serum concentration during the first months following the beginning of the treatment may predict BP disease outcome. In this setting, a slight decrease in anti-BP180 IgG serum concentrations after 2 months of therapy is a factor associated with disease relapse within the first year of treatment. [36] Also, a high BP180-NC16A ELISA titre and a positive direct IF findings at the cessation of therapy are both good indicators of later relapse of BP. [80, 81] Noteworthily, the biological monitoring of the inflammatory response associated with the autoimmune response of BP patients during the follow-up could also be informative and help in the prediction of disease outcome.
| BP-RELATED AUTOANTIBODIES AS BIOMARKERS OF BP DISEASE

| INFLAMMATION AND BIOMARKERS IN BP DISEASE
Bullous pemphigoid is an autoimmune but also an inflammatory blistering disease. A large number of proinflammatory molecules, that is, cytokines, chemokines, adhesion molecules, prostaglandins and proteases, displayed increased concentrations in blister fluids and/or serum of patients with BP. However, evidences are lacking to relate all of them with disease activity, severity or BP outcome. We therefore focused our review on molecules that could be considered as biological biomarkers of the disease.
| Markers of BP activity and severity
Several cytokines as well as molecules associated with inflammation have been reported as potential markers of BP activity. In this way, cytokines associated with Th 2 -type immune response have been described as being involved in the inflammatory mechanisms of BP (Table S1 ). Indeed, increased serum levels of the Th 2 -type cytokines IL-4 and IL-5, as well as an increase in soluble CD30, a specific activation marker of Th 2 cells, have been shown in patients with BP compared to healthy controls. [82] [83] [84] Both IL-5 and soluble CD30 serum concentrations varied with respect to disease activity [82, 84] with a significant reduction in these concentrations in parallel with clinical improvement. Also, a significant increase in the frequency of IL-4-and IL-13-producing cells was found at the skin lesion site, [85] and large amounts of IL-4 and IL-5 were measured in the blister fluid of BP patients. [25, 84, [86] [87] [88] [89] However, among those cytokines, only IL-5 concentrations in the blister fluid were correlated with disease severity represented by the number of lesions. [87] In addition to the presence of Th2-type cytokines, the concentrations of the chemokines CCL5 (regulated on activation, normal T cell expressed and secreted, RANTES), CCL11 (eotaxin), CCL17 (thymus and activation-regulated chemokine, TARC), CCL18 (pulmonary and activation-regulated chemokine, PARC) and CCL22 (macrophage-derived chemokine, MDC) and CCL26 (eotaxin 3), which are preferentially chemotactic for cells associated with the Th2 microenvironment, were found to be elevated in the serum and/or the blister fluid of patients with BP. Those chemokines were linked to BP extent measured by either number of blisters or body surface affected. [90] [91] [92] [93] [94] [95] [96] [97] [98] [99] [100] Noteworthily, CCL17 serum concentrations positively correlated with those of IgE, [92] while IL-5, CCL5, CCL11 and CCL26 concentrations were associated with tissue eosinophilia. [90, [97] [98] [99] [100] These chemokines may play a major role in BP pathological process as eosinophils have been described in situ as one of the most represented cell types in human skin lesions. [101] Moreover,
De Graauw et al [102] evidenced that after challenging with BP autoantibodies, IL-5-preactivated eosinophils released mediators involved in blister formation. In this line, an elevation in granule proteins levels (ie, MBP, EDN, ECP), markers of eosinophil activation, has been shown in the sera of patients with active BP. [103] [104] [105] [106] However, no evidence for a relation of these eosinophil-related molecules with disease severity was found. [106] These data confirmed that the above-mentioned molecules and cells belonging to the Th2 microenvironment are rather involved in the early stage of the lesion, [102] suggesting that other (Table S1 ). Namely, the cytokines IFN-γ, IL-1β and TNF-α [7, 87] and the chemokines CXCL9 (MIG), CXCL10 (IP10) [91] were detected at high concentrations in the blister fluids of BP patients. Their concentrations were all correlated with disease severity [7, 87, 91] except for IFN-γ blister fluid concentrations.
Furthermore, TNF-α serum concentrations were correlated with the number of blisters. [107] In line with the proinflammatory cytokine IL-1β
and TNF-α expression, the inflammasome activation was evidenced by the elevated concentrations of IL-18, an IL-1 family cytokine, both in the serum and in the blister fluid. [108] The IL-18 cytokine is constitutively expressed by macrophages, dendritic cells and keratinocytes under its precursor form. After autoactivation, caspase-1 induces the maturation and secretion of IL-1β and IL-18. [109] In BP, Fang et al [108] highlighted (Table S1 ). The expression of IL-21, a cytokine characteristic of T follicular helper cell (T fh) orientation, was correlated with anti-BP180-NC16A autoantibody titres. [110] Accordingly, a decrease in IL-21 serum concentration and the respective T fh circulating cells was observed after an effective therapy leading to clinical improvement. [110] Regulatory T cells and Th-17 cells were also proposed to play a crucial role in the pathology of BP. [111] Although blister fluids displayed high level of IL-6, IL-17, IL-22 and IL-23, immunochemistry of BP skin biopsy specimens evidenced that IL-17 was produced by neutrophils but not by lymphocytes, further highlighting the importance of innate immune cells in BP. [112] However, neither IL-17 nor IL-23 was defined as biomarker of disease severity at the time of diagnosis. [112] Conversely, the pro-inflammatory cytokine IL-6 was presented as a biomarker of BP severity. [7, 83, 87, 107] Also, IL-8, a neutrophil attractant chemokine, [113, 114] was shown to be overexpressed in blister fluid by anti-BP180-stimulated keratinocytes and by infiltrated immune cells activated by cytokines such as IL-1β, IL-6 and TNF-α. [83, 87, 115] The chemoattraction and activation of neutrophils upon the effects of IL-8 in concert with IL-17 and IL-23 [9, 112] leads to the release of MMP-9
and elastase and therefore to the blister formation. In this line, in situ IL-8 concentration was shown to correlate with the number of lesions and has also been proposed as a potential biomarker of the disease extent [87] while serum concentrations decreased after effective therapy. [83] Finally, the pathological mechanisms underlying the inflammatory BP activity go beyond the Th1-Th2 paradigm, emphasizing a cooperation with other polarized T cells and innate immune cells leading to BP lesion.
| Markers of BP outcome
Most of BP patients are controlled under corticotherapy within the first year of treatment. However, clinical relapse despite therapy is still observed in 30% of BP patients. Certain of the above-mentioned activity markers displayed a significant decrease upon the antiinflammatory effects of glucocorticoids and therefore may also be considered as biomarker for disease control (Table S1 ). This was evidenced for IL-5, [84] IL-18, [108] and IL-21 [110] and the chemokines CCL17, [92] [93] [94] CCL18, [97] and CCL22. [92] Conversely, the immunoregulatory mechanisms are emphasized when the disease is controlled.
Indeed, BP patients showed higher IL-10 serum concentrations after therapy, [85, 116] along with the increased frequency of IL-10 (+) cells in the peripheral blood, [116] showing that this cytokine was related to clinical improvement.
Supporting the importance of the above-mentioned cytokines IL-17 and IL-23 in the inflammatory response associated with BP, we recently showed that a significant decrease in IL-17 serum concentration was observed during the follow-up in patients with ongoing remission, whereas it remained elevated in patients who relapsed. [112] Meanwhile, an increase in IL-23 serum concentrations was observed only in patients who later relapsed under treatment. [112] Thus, these 2 cytokines may be used as indicators of later relapse. Similar results were obtained when measuring the chemokine CXCL10 in the serum of BP patients (Table S1 ). Indeed, CXCL10 serum concentrations increased after 2 months of therapy only in patients who relapsed within the first year of treatment. [10] Interestingly, all these 3 molecules upregulated leucocyte-secreted MMP-9. [10] We further demonstrated that each molecule specifically targeted different immune cells.
Indeed, IL-17 induced MMP-9 secretion by activating lymphocytes, while IL-23 and CXCL10 preferentially enhanced MMP-9 secretion from monocytes and neutrophils. [10, 112] Consequently, the follow-up of protease expression appeared as a potential tool to predict relapse in BP patients. In this line, we showed that serum MMP-9 concentration decreases over time in patients with ongoing remission, whereas it remains elevated in patients with BP who later relapse. [112] Eosinophils may also play a role in BP outcome. Investigation of the eosinophilic markers revealed that the assessment of ECP serum concentrations variation during the 2 first months of follow-up was clinically relevant in predicting the response to treatment [117] (Table S1 ).
Indeed, ECP concentrations decreased under treatment in the serum of patients with ongoing remission, but not in those of patients with BP who experienced a relapse during the first year of treatment.
Altogether, these molecular biomarkers are the evidence for a specific cellular activation and regulation in the pathogenesis of relapse.
Altogether, these studies demonstrated that inflammation decreases in BP patients with clinical improvement upon therapy.
Subsequently, it is essential to perform longitudinal studies to investigate whether a cytokine /chemokine is involved in BP outcome. Inflammatory molecules have been associated with different pathophysiological mechanisms related to BP activity, severity and outcome. Furthermore, it is now well recognized that the more severe the disease is at the time of diagnosis, the higher the risk of relapse is.
Meanwhile, disease severity is associated with high level of inflammatory molecules. However, more importantly than the concentrations at the time of diagnosis, this is the capacity of BP patients to respond to treatment, demonstrated by the variation in these inflammatoryassociated molecules, which sounds more important to predict disease outcome. In this line, demonstrating soon after treatment onset, process on which BP relapse may ignite. In this line, a lower decrease in BP-180 autoantibodies under treatment has been observed in BP patients at risk of relapse. [36] Therefore, measuring serum levels of cytokines / chemokines in addition to autoantibody levels in the clinical routine should benefit both clinicians and BP patients.
| Clinical challenges
Some of the cytokines associated with BP pathology are common to several other skin autoimmune bullous diseases, even if it clearly appears that each AIBD has its own global cytokine profile. Pemphigus is characterized by a mechanical non-inflammatory acantholysis induced by antidesmoglein autoantibodies. Nevertheless, in the pemphigus herpetiformis subtype, it is thought that IL-8 produced by autoantibodyactivated keratinocyte attracts inflammatory cells, leading to focal intercellular oedema and eosinophilic spongiosis. [118, 119] Based on these few publications performed on a limited number of patients, this inflammatory cascade resembles BP. However, further investigations are required to compare the global cytokine profile associated with these dermatoses. Mucous membrane (cicatricial, CP) pemphigoid is associated in a number of cases with the presence of anti-BP180
and anti-BP230 autoantibodies, but also with autoantibodies directed against different epithelial membrane zone components, including laminin-332, laminin-311, type VII collagen, b4 integrin subunit.
The involvement of cellular immunity in the pathogenesis of mucous membrane pemphigoid has been illustrated by several studies showing a predominance of CD4 + T cell and Langerhans cell infiltrates in the conjunctiva of those patients. [120, 121] Furthermore, Th17 lymphocytes were significantly increased in conjunctival biopsies of patients with ocular lesions, [122] and associated with a local overexpression of IL-6, IL-8, IL-12 and IL-17 in conjunctiva of those patients compared to controls. [123] In setting with the in situ Th17 presence, a local production of TGF-β may activate fibroblasts to induce fibrosis. [120] Contrasting with this in situ cytokine panel, a significant increase in IFN but not of IL-17, IL-4 or TGF-β was observed in the plasma from those patients versus healthy subjects. Then, these cytokine panels profoundly differ from the above described in BP patients, although these 2 autoimmune diseases are closely related. The inflammatory variants of EBA also clinically mimic BP, although the autoantibodies fundamentally differ. [124, 125] Experiments using animal models also were observed in experimental EBA. [124] Although the cytokine panel defined with an EBA murine model profoundly differs from the cytokine panel defined in BP patients, it highlights that cytokine such as IL-17 is involved in the pathophysiological mechanism of all pemphigoid diseases. However, the clinical relevance of an anti-IL-17-based therapy still has to be demonstrated either with the adult BP animal model [33] or in clinical trial.
Although confirmed by some animal studies, [126, 127] it has to be underlined that most reported studies on cytokine expression are based on small or retrospective series of patients. Therefore, to link such cytokine variations to clinical practice, future large and prospective studies should confirm these above-mentioned findings.
Besides, it must also be stipulated that the short half-life of cytokines, the secretion of cytokines by cells during blood storage and the potential degradation of cytokines are important factors that alter cytokine measurement. For instance, it was previously shown that the serum IL-6 and TNF-α half-life was as short as 103 ± 27 minutes and 70 ± 11 minutes, respectively. [128] Furthermore, it was also demonstrated that such half-life varies according to time and temperature blood storage before sampling. [129, 130] Therefore, in future studies, sample collection should be performed in a standardized procedure in order to better define the potential clinical usefulness of some of those cytokines as inflammatory biomarker either at the time of diagnosis or in the disease course of BP. Noteworthily, we previously reported using serum samples prepared within the 2 hours after blood collection from a large prospective series of BP patients that a reduction at day 60 of at least 12.8 ng/mL in ECP serum concentrations provided a positive predictive value for remission of 81%, showing that ECP serum variation could be a useful biomarker stratifying BP patients at risk of relapse from patients with ongoing remission under treatment. [106] Besides, we also found an elevated level under therapy of IL-17, IL-23 and CXCL10 in BP patients at risk of relapse during the first year of treatment. [10, 112] Based on these observations, a trial evaluating the role of cytokines belonging to the IL-17 axis could be of interest to determine whether those cytokines are relevant in clinical practice to prevent relapses especially in BP patients with corticosteroid dependence, corticosteroid resistance or presenting corticosteroid adverse effect. Such trial could also evaluate whether these biotherapies could be useful to maintain clinical remission allowing a decrease in cumulative doses and therapy duration of corticosteroid therapy. 
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